Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03456544|
Recruitment Status : Not yet recruiting
First Posted : March 7, 2018
Last Update Posted : May 22, 2018
Peking University First Hospital
Information provided by (Responsible Party):
Cui Yimin, Peking University First Hospital
The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.
|Condition or disease||Intervention/treatment|
|Vancomycin Staphylococcal Infections Adverse Effect Acute Kidney Injury Cross-sectional Study||Drug: Vancomycin|
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China|
|Estimated Study Start Date :||July 31, 2018|
|Estimated Primary Completion Date :||March 31, 2019|
|Estimated Study Completion Date :||May 31, 2019|
Patients who had vancomycin associated acute kidney injury.
Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
Patients who didn't have vancomycin associated acute kidney injury.
Primary Outcome Measures :
- Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate [ Time Frame: 1 year ]
Secondary Outcome Measures :
- VAN-AKI detection rate [ Time Frame: 1 year ]
- TDM detction rate [ Time Frame: 1 year ]
- 0h Serum creatinine detction rate [ Time Frame: 1 year ]
- 48h Serum creatinine detction rate [ Time Frame: 1 year ]
No Contacts or Locations Provided